Results 61 to 70 of about 1,991 (194)

Tale of three services: early UK experience with mavacamten treatment for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction

Open Heart
Background Hypertrophic cardiomyopathy (HCM) is characterised by abnormal thickening of ventricular myocardium. Left ventricular outflow tract (LVOT) obstruction occurs in up to 70% of patients, causing progressive symptoms, heart failure and mortality ...
Jane Draper, Antonio De Marvao, Robert M Cooper, Gerry Carr-White, Nabeel Sheikh, Rachel Bastiaenen, Yande Kasolo, Jason N Dungu, Edward Burford   +8 more
doaj   +1 more source

Biomechanical response of ultrathin slices of hypertrophic cardiomyopathy tissue to myosin modulator mavacamten [PDF]

Hypertrophic cardiomyopathy (HCM) is the most common inherited myocardial disorder of the heart, but effective treatment options remain limited. Mavacamten, a direct myosin modulator, has been presented as novel pharmacological therapy for HCM.
Amesz, Jorik H., de Groot, Natasja M.S., de Jong, Peter L., Langmuur, Sanne J.J., Manintveld, Olivier C., Schinkel, Arend F.L., Taverne, Yannick J.H.J., Zhang, Lu   +7 more
core   +2 more sources

Evaluation of Percutaneous Intramyocardial Septal Pulsed Field Ablation in a Rabbit Model: Safety, Efficacy, and Feasibility

Journal of Interventional Cardiology, Volume 2026, Issue 1, 2026.
Background Percutaneous intramyocardial (PIM) septal pulsed field ablation (SPFA) represents an innovative technique for the management of hypertrophic obstructive cardiomyopathy. However, the paucity of pertinent animal models has impeded comprehensive investigation. This study aimed to assess the safety, efficacy, and feasibility of PIM‐SPFA, as well
Xing-an Zhao, Hua-lei Dai, Si-ming Tao, Yi-jian Zhang, Ji Jia, Li-juan Song, Man Yang, Yun-na Ge, Xi-ya Wang, Juan Qing, Piotr Musialek   +10 more
wiley   +1 more source

Pharmacological Inhibition of β Myosin II Disrupts Sarcomere Assembly in Human iPSC‐Derived Cardiac Myocytes

Cytoskeleton, Volume 82, Issue 12, Page 795-803, December 2025.
ABSTRACT Sarcomeres are the fundamental contractile units of striated muscle. The functional roles of the cardiac‐specific myosin heavy chains, MYH6 (α myosin II) and MYH7 (β myosin II) during sarcomere assembly remain controversial. To address this, we utilized a selective MYH7 inhibitor, mavacamten, in combination with siRNA‐mediated knockdown of ...
James B. Hayes, Dylan T. Burnette
wiley   +1 more source

Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM [PDF]

BACKGROUND: Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of aficamten in ...
Olivotto, Iacopo
core   +6 more sources

Exposure–Response Modeling and Simulation to Identify Optimal Mavacamten Posology When Coadministered with CYP3A4 and CYP2C19 Inhibitors in Patients with Obstructive HCM

The Journal of Clinical Pharmacology, Volume 65, Issue 12, Page 1802-1814, December 2025.
Abstract Mavacamten, a cardiac myosin inhibitor, is primarily metabolized by the cytochrome P450 (CYP) enzymes CYP2C19 and CYP3A4, and coadministration with strong CYP3A4 or CYP2C19 inhibitors was contraindicated in patients with obstructive hypertrophic cardiomyopathy (HCM) in the US Prescribing Information. This study assessed the safety and efficacy
Samira Merali, Haden Bunn, Caroline Sychterz, Manting Chiang, Shilpa Puli, Amy J. Sehnert, Bindu Murthy, Joga Gobburu   +7 more
wiley   +1 more source

Mavacamten and atrial fibrillation: assessing the risk through FAERS and meta-analysis

BMC Cardiovascular Disorders
Background Mavacamten is a novel selective cardiac myosin inhibitor indicated for patients with obstructive hypertrophic cardiomyopathy (oHCM). Given its negative inotropic properties, which theoretically reduce myocardial contractility and affect left ...
Lingqing Ding, Xinhang Liao, Yongkuan Yang, Congqin Chen, Jie Xiao   +4 more
doaj   +1 more source

Toward a Quantitative Understanding of Aficamten Clinical Pharmacology: Population Pharmacokinetic Modeling

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 12, Page 1982-1992, December 2025.
ABSTRACT Aficamten is a next‐in‐class, cardiac myosin inhibitor in development as a potential chronic oral treatment for patients with hypertrophic cardiomyopathy (HCM). A population pharmacokinetic (PK) model was developed using data from nine clinical studies to characterize aficamten PK and identify covariates that may alter aficamten exposure ...
Donghong Xu, Hanbin Li, Stephen B. Heitner, Daniel L. Jacoby, Stuart Kupfer, Polina German, Justin Lutz   +6 more
wiley   +1 more source

Mavacamten in Right Ventricular Outflow Tract Obstruction

JACC: Case Reports
Right ventricular outflow tract (RVOT) obstruction is a rare complication of ventricular hypertrophy in patients with hypertrophic cardiomyopathy (HCM). This study presents an unusual case of a patient with HCM with severe RVOT obstruction that was relieved successfully through the use of mavacamten.
Jasmine K. Malhi, Richard T. Carrick, Chloe Duvall, Faisal Rahman, Matthew W. Martinez, Jose Madrazo, Lili A. Barouch   +6 more
openaire   +3 more sources

New insights into applications of base editor in hereditary disorders

Interdisciplinary Medicine, Volume 3, Issue 6, November 2025.
Abstract Hereditary disorders are a group of diseases caused by genetic mutations or chromosomal variations. Although the incidence of each genetic disorder is relatively low, patients affected by the disease generally experience a range of severe symptoms, including blindness, disability, and even premature death. In addition, the available treatments
Maoping Cai, Linhui Zhang, Liqing Li, Yue Liu, Canbin Lv, Yan Shi, Jianyuan Zhao, Dingwei Ye, Yuanyuan Qu   +8 more
wiley   +1 more source